FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280494350> ?p ?o ?g. }

• W4280494350 endingPage "e048833" @default.
• W4280494350 startingPage "e048833" @default.
• W4280494350 abstract "Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S-1 (OX-IRIS) for advanced pancreatic cancer. In the phase Ⅰ study that was conducted previously, the safety and recommended dose of OX-IRIS were assessed. In this study, we will evaluate the efficacy and safety of OX-IRIS.The HGCSG1803 study started as a multicentre, non-randomised, single-arm, prospective, phase II study in December 2019. Eligible subjects were patients with untreated metastatic or relapsed pancreatic cancer. OX-IRIS is administered as follows: 30 min infusion of antiemetic; 2-hour infusion of oxaliplatin (65 mg/m2); 1.5-hour infusion of irinotecan (100 mg/m2) on day 1 and 15 of each 4-week cycle; and oral S-1 (40 mg/m2) twice daily from after dinner on day one to after breakfast on day 15, followed by a 14-day rest, to be repeated every 2 weeks until disease progression, unacceptable toxicity or patient refusal. The primary endpoint is response rate. The secondary endpoints are overall and progression-free survival, safety and dose for each drug. Using a binomial test, a sample size of 40 patients was set with a threshold value of 10% and expected value of 30%. Registration of 40 cases is planned from 18 institutions in Japan.All the procedures will be conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1964 and its later versions. All the patients will receive written information about the trial and will provide informed consent before enrolment. This trial was approved by the Hokkaido University Certified Review Board (approval No: 018-037).jRCTs011190008." @default.
• W4280494350 created "2022-05-22" @default.
• W4280494350 creator A5001876291 @default.
• W4280494350 creator A5014225991 @default.
• W4280494350 creator A5016814013 @default.
• W4280494350 creator A5024713150 @default.
• W4280494350 creator A5026656732 @default.
• W4280494350 creator A5029924703 @default.
• W4280494350 creator A5032420302 @default.
• W4280494350 creator A5037372375 @default.
• W4280494350 creator A5038183052 @default.
• W4280494350 creator A5045950776 @default.
• W4280494350 creator A5048421476 @default.
• W4280494350 creator A5052766016 @default.
• W4280494350 creator A5054182211 @default.
• W4280494350 creator A5056456991 @default.
• W4280494350 creator A5057711892 @default.
• W4280494350 creator A5069341122 @default.
• W4280494350 creator A5070753522 @default.
• W4280494350 creator A5073532961 @default.
• W4280494350 creator A5076417403 @default.
• W4280494350 creator A5077794725 @default.
• W4280494350 creator A5080229788 @default.
• W4280494350 creator A5084976321 @default.
• W4280494350 date "2022-05-01" @default.
• W4280494350 modified "2023-09-27" @default.
• W4280494350 title "Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer" @default.
• W4280494350 cites W2019607817 @default.
• W4280494350 cites W2050743878 @default.
• W4280494350 cites W2085705101 @default.
• W4280494350 cites W2143953275 @default.
• W4280494350 cites W2151253787 @default.
• W4280494350 cites W2165480504 @default.
• W4280494350 cites W2167138718 @default.
• W4280494350 cites W2254146818 @default.
• W4280494350 cites W2412717755 @default.
• W4280494350 cites W2464384214 @default.
• W4280494350 cites W2481516632 @default.
• W4280494350 cites W2509578420 @default.
• W4280494350 cites W2574112406 @default.
• W4280494350 cites W2775857678 @default.
• W4280494350 cites W2792494514 @default.
• W4280494350 cites W2911188335 @default.
• W4280494350 cites W2914606580 @default.
• W4280494350 cites W2979047405 @default.
• W4280494350 cites W3164352898 @default.
• W4280494350 doi "https://doi.org/10.1136/bmjopen-2021-048833" @default.
• W4280494350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35534074" @default.
• W4280494350 hasPublicationYear "2022" @default.
• W4280494350 type Work @default.
• W4280494350 citedByCount "1" @default.
• W4280494350 countsByYear W42804943502023 @default.
• W4280494350 crossrefType "journal-article" @default.
• W4280494350 hasAuthorship W4280494350A5001876291 @default.
• W4280494350 hasAuthorship W4280494350A5014225991 @default.
• W4280494350 hasAuthorship W4280494350A5016814013 @default.
• W4280494350 hasAuthorship W4280494350A5024713150 @default.
• W4280494350 hasAuthorship W4280494350A5026656732 @default.
• W4280494350 hasAuthorship W4280494350A5029924703 @default.
• W4280494350 hasAuthorship W4280494350A5032420302 @default.
• W4280494350 hasAuthorship W4280494350A5037372375 @default.
• W4280494350 hasAuthorship W4280494350A5038183052 @default.
• W4280494350 hasAuthorship W4280494350A5045950776 @default.
• W4280494350 hasAuthorship W4280494350A5048421476 @default.
• W4280494350 hasAuthorship W4280494350A5052766016 @default.
• W4280494350 hasAuthorship W4280494350A5054182211 @default.
• W4280494350 hasAuthorship W4280494350A5056456991 @default.
• W4280494350 hasAuthorship W4280494350A5057711892 @default.
• W4280494350 hasAuthorship W4280494350A5069341122 @default.
• W4280494350 hasAuthorship W4280494350A5070753522 @default.
• W4280494350 hasAuthorship W4280494350A5073532961 @default.
• W4280494350 hasAuthorship W4280494350A5076417403 @default.
• W4280494350 hasAuthorship W4280494350A5077794725 @default.
• W4280494350 hasAuthorship W4280494350A5080229788 @default.
• W4280494350 hasAuthorship W4280494350A5084976321 @default.
• W4280494350 hasBestOaLocation W42804943501 @default.
• W4280494350 hasConcept C121608353 @default.
• W4280494350 hasConcept C126322002 @default.
• W4280494350 hasConcept C141071460 @default.
• W4280494350 hasConcept C143998085 @default.
• W4280494350 hasConcept C203092338 @default.
• W4280494350 hasConcept C2776694085 @default.
• W4280494350 hasConcept C2777148230 @default.
• W4280494350 hasConcept C2778336483 @default.
• W4280494350 hasConcept C2780258809 @default.
• W4280494350 hasConcept C2780259306 @default.
• W4280494350 hasConcept C2780962732 @default.
• W4280494350 hasConcept C2781413609 @default.
• W4280494350 hasConcept C31760486 @default.
• W4280494350 hasConcept C526805850 @default.
• W4280494350 hasConcept C535046627 @default.
• W4280494350 hasConcept C71924100 @default.
• W4280494350 hasConceptScore W4280494350C121608353 @default.
• W4280494350 hasConceptScore W4280494350C126322002 @default.
• W4280494350 hasConceptScore W4280494350C141071460 @default.
• W4280494350 hasConceptScore W4280494350C143998085 @default.
• W4280494350 hasConceptScore W4280494350C203092338 @default.
• W4280494350 hasConceptScore W4280494350C2776694085 @default.

• next